BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06091943
- Locations
- 🇲🇩
The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 640
- Registration Number
- NCT06073821
- Locations
- 🇺🇸
John Muir Medical Center, Concord, California, United States
🇺🇸University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Department of Medicine Hematologyoncology, Los Angeles, California, United States
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT06029127
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Gansu Provincial Hospital, Lanzhou, Gansu, China
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 118
- Registration Number
- NCT06010303
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇹🇭Songklanagarind Hospital (Prince of Songkhla University), Hat Yai, Thailand
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 90
- Registration Number
- NCT05981703
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
🇨🇳Jining No Peoples Hospital West Branch, Jining, Shandong, China
🇨🇳Taizhou Hospital of Zhejiang Province (East), Taizhou, Zhejiang, China
Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 105
- Registration Number
- NCT05952037
- Locations
- 🇨🇦
Lions Gate Hospital Chemotherapy Clinic, North Vancouver, British Columbia, Canada
🇨🇦Qeii Health Science Center, Halifax, Nova Scotia, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 318
- Registration Number
- NCT05935098
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Next Dallas, Irving, Texas, United States
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 160
- Registration Number
- NCT05909904
- Locations
- 🇹🇭
Siriraj Hospital, Bangkok, Thailand
🇹🇭Ramathibodi Hospital Mahidol University, Bangkok, Thailand
🇰🇷Keimyung University Dongsan Hospital, Dalseogu, Daegu Gwang'yeogsi, Korea, Republic of
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 200
- Registration Number
- NCT05904496
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 6
- Registration Number
- NCT05844111
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States